Mirikizumab-Mrkz Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg

Reference Brands: Omvoh (USA)

Category: Immune Disorder

Product Description:

Mirikizumab‑MRKZ, marketed under the brand name Omvoh, is a monoclonal antibody approved for the treatment of moderately to severely active ulcerative colitis in adults. It works by selectively binding to interleukin-23 (IL-23), a cytokine involved in immune-mediated inflammation, and blocking its activity. This targeted mechanism helps reduce inflammation in the gastrointestinal tract and supports mucosal healing, offering a precision-based approach to managing ulcerative colitis.

Administered via subcutaneous injection, Omvoh is designed for patients who have not responded adequately to conventional therapies. The therapy provides a focused immunomodulatory effect while minimizing broader systemic immunosuppression. Patients receiving Omvoh should be monitored for potential adverse events, which most commonly include upper respiratory tract infections, headache, rash, and injection-site reactions. Its development and production are overseen by Eli Lilly and Company in clinical-grade facilities to ensure high-quality manufacturing and safety standards.

Omvoh represents an important therapeutic option in the management of ulcerative colitis, providing targeted disease control and improving patient quality of life through a novel mechanism of action.